CD25 x CTLA-4 bispecific DART (MacroGenics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCD25 x CTLA-4 bispecific DART (MacroGenics)

Drug Alias NameIgG1-Fc enhanced CD25 x CTLA-4 DART (MacroGenics)Treg modulator (MacroGenics)bivalent CD25 x CTLA-4 bispecific DART protein (MacroGenics)CD25/CTLA-4 bispecific antibodies (MacroGenics)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 modulatorsInterleukin-2 receptor alpha chain modulatorsLow affinity immunoglobulin gamma Fc region receptor III-A antagonists

TargetsLow affinity immunoglobulin gamma Fc region receptor III-ACytotoxic T-Lymphocyte-Associated Antigen 4Interleukin-2 receptor alpha chain

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending

Highest Status in ChinaN/A

Originator CompaniesMacrogenics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMacrogenics Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A